Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · IEX Real-Time Price · USD
71.25
+1.36 (1.94%)
May 1, 2024, 12:52 PM EDT - Market open
Ligand Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
1.28B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
Dec 31, 2019 | 120.28M | -131.17M | -52.17% |
Dec 31, 2018 | 251.45M | 110.35M | 78.21% |
Dec 31, 2017 | 141.10M | 32.13M | 29.48% |
Dec 31, 2016 | 108.97M | 37.06M | 51.53% |
Dec 31, 2015 | 71.91M | 7.38M | 11.43% |
Dec 31, 2014 | 64.54M | 15.57M | 31.78% |
Dec 31, 2013 | 48.97M | 17.59M | 56.02% |
Dec 31, 2012 | 31.39M | 1.35M | 4.50% |
Dec 31, 2011 | 30.04M | 6.50M | 27.61% |
Dec 31, 2010 | 23.54M | -15.40M | -39.55% |
Dec 31, 2009 | 38.94M | 11.63M | 42.56% |
Dec 31, 2008 | 27.32M | 14.42M | 111.84% |
Dec 31, 2007 | 12.89M | 8.92M | 224.21% |
Dec 31, 2006 | 3.98M | -6.24M | -61.07% |
Dec 31, 2005 | 10.22M | -101.90M | -90.89% |
Dec 31, 2004 | 112.11M | 30.99M | 38.21% |
Dec 31, 2003 | 81.12M | 9.35M | 13.03% |
Dec 31, 2002 | 71.77M | -4.57M | -5.99% |
Dec 31, 2001 | 76.34M | 28.23M | 58.68% |
Dec 31, 2000 | 48.11M | 7.22M | 17.64% |
Dec 31, 1999 | 40.90M | 23.22M | 131.40% |
Dec 31, 1998 | 17.67M | -34.03M | -65.82% |
Dec 31, 1997 | 51.70M | 14.86M | 40.33% |
Dec 31, 1996 | 36.84M | 12.33M | 50.28% |
Dec 31, 1995 | 24.52M | 11.21M | 84.21% |
Dec 31, 1994 | 13.31M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Brookdale Senior Living | 3.02B |
Omnicell | 1.15B |
Pacira BioSciences | 674.98M |
NovoCure | 509.34M |
Ironwood Pharmaceuticals | 442.74M |
Kiniksa Pharmaceuticals | 301.77M |
Xencor | 168.34M |
4D Molecular Therapeutics | 20.72M |
LGND News
- 8 days ago - Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 23 days ago - Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference - Business Wire
- 4 weeks ago - Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ - Business Wire
- 2 months ago - Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Ligand Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® - Business Wire
- 2 months ago - Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires - Business Wire